Figure 5From: The effect of nilotinib plus arsenic trioxide on the proliferation and differentiation of primary leukemic cells from patients with chronic myoloid leukemia in blast crisis Effects of ATO and nilotinib on the expressions of TAL1 and BTG1. Cells were treated with 1 μM ATO and 5 nM Nilotinib alone or in combination for 72 h. The mRNA (A) and protein (B) expressions of TAL1 and BTG1 were evaluated by RT-PCR and Western blotting, respectively. β-actin was used as an internal control, and representative data were presented. (A) 1, Control; 2, Nilotinib treatment alone; 3, ATO treatment alone; 4, Nilotinib + ATO. (B) 1, Control; 2, ATO treatment alone; 3, Nilotinib treatment alone; 4, Nilotinib + ATO.Back to article page